Home / Transcripts / Teva Pharmaceutical Industries Limited (TEVA) · April 29, 2026

Teva Pharmaceutical Industries Limited (TEVA) Earnings Call Transcript

April 29, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 68 min

Earnings Call Speaker Segments

Chris Stevo executive
#1

Thanks, Alex. Hello and good morning, good afternoon to all of you. We appreciate you being with us for this call covering our first quarter. I want to point out that — prior to releasing our earnings press release this morning, we put out a separate press release regarding the MLX transaction, along with a slide deck for that deal. Those items are available in the very same location where our earnings materials can be found. Before handing things over to Richard Francis, our CEO, I should remind everyone that forward-looking statements will be part of this call. The company advises investors that any such statement carries risks and uncertainties and should not be viewed as a guarantee of future performance. Actual results could differ materially from what those forward-looking statements express or imply, owing to a variety of factors. Our earnings press release, along with the most recent 10-Q and 10-K we filed with the SEC, describe these factors. Everything we say reflects only today, and we assume no duty to update these statements afterward; with that, Richard Francis.

Richard Francis executive
#2

Thanks, Chris. Good morning, and good afternoon, everyone. I appreciate you all joining today's call. Joining me are my colleague Dr. Eric Hughes, who leads R&D and serves as Chief Medical Officer, along with Eli Kalif, our Chief Financial Officer. Let me begin, as I typically do, with the Pivot to Growth Strategy slide. Three years have passed since we introduced this strategy, and it rests on 4 pillars: deliver on your growth engines, step up innovations, sustain generics powerhouse and focus the business. As today's presentation will show, we've achieved substantial progress on every one of those pillars. Regarding delivery in our growth engines, you'll observe that steady said and Ajovy keep generating solid, healthy growth. On stepping up innovation, Eric will tell you about our exciting pipeline plus several data readouts and milestones coming this year. For our sustained Generics powerhouse, you'll notice growth beginning to emerge from our biosimilar portfolio. Finally, on focusing our business, you'll see we stay committed to directing our capital toward the highest-return opportunities. Eli will take you through some of that, and he'll also update you on the organizational effectiveness efforts we've completed and how we remain on track to reach our $700 million of savings in 2027. But before that, and building on what Chris just mentioned, I want to spend a little time today discussing the announcement regarding our acquisition of Emalex Bioscience. This marks the first acquisition under the Pivot to Growth strategy. Through this Emalex acquisition, we gain ownership of IkaPipelane, a first-in-class asset offering compelling efficacy and favorable tolerability in Tourette syndrome. Now let me share a bit about this condition. It's a serious, life-altering pediatric neurological disorder with few good options available today. So this represents a market of serious unmet medical need where existing therapies truly fail to satisfy the need. They either provide efficacy but come with tolerability challenges, or they lack sufficient efficacy while offering a tolerable profile. Because of that failure, only about half of patients actually receive treatment, and a few of them are third stale therapy after 1 year. So we view this as a clear opportunity to help patients and expand the market, something we've successfully accomplished with the STED and used. As you know, we possess strong CNS capabilities at Teva, whether in sales, marketing, market access, or patient services, and we believe leveraging these will help drive penetration and growth. It's worth noting that this transaction is highly aligned with our pivot to growth business development strategy. Ecopia has a derisked mechanism, strong pivotal data, no major development overhangs and orphan dynamics that support attractive pricing. — ensure this is a high-quality, value-accretive asset that accelerates our shift towards innovative revenue and profitable growth without compromising our balance sheet discipline. So what I'll do now is walk you through what's coming on the following slide — the treatment landscape — since that really clarifies the reason we hold such enthusiasm for the eco pipeline. Typically, patients begin with behavioral therapies. When those don't work, families face tough decisions. One option is an alpha-2 antagonist; those tend to be safe, yet for a lot of patients they may not deliver the efficacy needed. Then comes the antipsychotic step — effective, yes, but accompanied by substantial metabolic and neurologic side effects, which pushes many families to stop treatment or steer clear of it entirely. It's easy to see why there'd be genuine reluctance about starting a 10-year-old on an antipsychotic for the decade ahead. For a chronic pediatric condition, that simply isn't a workable long-term answer. With eco pipeline, the equation shifts: it brings meaningful efficacy alongside a favorable side effect profile, which sets it up to be a preferred late-line therapy, and we absolutely expect the pricing to capture that value. Moving to the following slide, you'll find some of the deal specifics. I'll let Eli walk through those in greater depth. One point I do want to call out, though, is that this asset's gross margin sits well above our corporate average, and it won't affect our capacity to reach our 2027 targets or the ones after that. With that, let me turn to the quarter 1 results. We got off to a good start this year, with solid performance powered by the ongoing strength of our innovative portfolio, and you'll see how Astero Jobin Yusri grew over a couple of slides. Our revenues landed where we expected — down 1%, or up 7% once you exclude both the gene vestment and include generic Revlimid. It's encouraging to see us offsetting the drop in generic revenues, just as planned and just as I've told you over the past few months. So, the figures: revenue down 1%, as I mentioned, at $4 billion; adjusted EBITDA up 2%, hitting $1.1 billion; non-GAAP EPS up 2%, reaching $0.53; free cash flow up 76%, reaching EUR 200 million. Net debt to EBITDA now stands at 2.42x — and as we pointed out, these compare against Q1 2025. Let's dig deeper, though, into what makes up that $4 billion. As you can see, our innovative portfolio grew strongly. All of these were up 41% instead of — in coincidence also up 41%, to $578 million. Yusri turned in a strong performance, rising 62% to $63 million, and the JV did well too, growing 35% to GBP 196 million. Our generics revenue came in as expected — down 13% excluding Japan, or flat when you exclude both Japan and generic Revlimid. Now let me take you to the next slide. I find this one genuinely interesting. It illustrates the shift Teva has undergone, from a pure-play generics company into a world-leading biopharma company. Alright, as you're able to see, this is quite meaningful, and the pace at which things are shifting matters a lot. Starting in 2022, the share of revenue coming from our innovative portfolio has climbed from 9% to more than 20%. And this slide makes clear we expect that expansion to keep going through 2030 and past it. One thing I consistently highlight as crucial is gross margin, and how that margin is being reshaped at Teva in a fundamental way by this portfolio shift; and looking at 2030, we expect gross margin to exceed 60%; now let me walk through the products one by one, beginning with AUSTEDO, which delivered another solid quarter in the U.S., hitting $559 million, a 41% increase versus a year ago, with worldwide results matching that momentum. The growth came from a mix of TRx, which rose 13%, and milligram growth of 20%, pointing to new patients coming in and better adherence. We keep seeing gains from the move toward once daily AUSTEDO XR, which accounts for more than 60% of new patients now; and it's obvious that AUSTEDO XR's convenience and simplicity are turning out to be key forces behind the franchise's staying power.

Richard Francis executive
#3

As we mentioned during Q4, there was some channel inventory buildup that hasn't been fully worked off in Q1. For the state, we're reaffirming our full-year guidance range of $2.4 billion to $2.55 billion. Turning to used Q1 results, for say it was a solid quarter, with revenues climbing 62% versus the prior year, and the underlying expansion came from ongoing prescription gains of 75% TRx. All of this speaks to our very strong product profile — subcutaneous, low volume, no loading dose, reaching therapeutic levels within 24 hours — and it also underscores the outstanding commercial capabilities we have here in the United States. I'm quite proud of a few figures I want to call out. Since you said as launched, it has almost doubled risperidone LAI's market share, going from 5% to 9%. And that's a tremendous achievement, to drive that kind of shift in a market that sat static for so long. So congratulations to the team. We're also now seeing expansion across the combined Risperidone and aliperodone LAI market. Worth pointing out that you said is positioned as the LAI of choice, with more than 86% of its NBRx coming from patients switching off orals plus those who are naive to antipsychotic drug therapy. And once again, we are reaffirming our guidance for the year. Now, I can't discuss you said without bringing up the upcoming olanzapine launch, which we're very excited about. Let me explain why — the significant global opportunity is obvious. Olanzapine today holds 19% of the entire market, yet it lags when it comes to viable long-acting options for a patient population that would meaningfully benefit from one. Second, as I just described with you say, this is a space where we'll have clear synergies — sales force, market access, MSLs, patient services, and so on. Beyond that, we have genuine know-how; the team has built up know-how over the last 3 years with UZEDY. And as you can see on this slide, the investigator excitement is palpable. People are genuinely looking forward to this product's launch, since there's a clear unmet medical need. Now on to AJOVY. AJOVY is a great illustration of how well we execute commercially on innovative products globally. Even though we were a late entrant into the crowded CGRP injectable market, AJOVY has steadily grown, consistently outpacing the overall injectable market, as the figures on this slide show. Wherever we launch, we generally end up as #1. And as you can see on the slide, Q1 growth was driven primarily by the U.S. and ex U.S., Europe, particularly where we had market share gains, volume growth and valuable growth when it comes to access. Now moving on to our pipeline. I find it hard not to go into a lot of detail on this, since I know Eric enjoys discussing it, but it's something I'm enthusiastic about. What I'll say is that we have 7 milestone readouts during this year. We began the year as always with the duvakitug maintenance data, which in our view was excellent. But now the anti-IL-5 vitiligo data will arrive in Q2. And then in H2, there are genuinely many readouts coming, be it the futility analysis and salmon, be it the anti-IL-5 data and CLEC disease, be it the dairy conclusion of our Phase III results, be it the launch of olanzapine LAI, or be it the first in human PD-1 IL-2; but what's worth noting is that together these will amount to more than $10 billion of peak sales. Now on to our generics business. Moving into the third pillar of our Pivot to Growth strategy. This did what we planned. Global generics fell 13%, largely because of generic REVLIMID, or flat once you strip out generic REVLIMID. Now turning to the U.S; we fell 28%, or rose 10% when REVLIMID is excluded, and that gain came mostly from higher revenues in our portfolio of biosimilar products. EU declined 1% from seasonality in some of our products along with launches, and international markets fell 9%, Japan excluded. Now, as I just said, generic growth in the U.S. has — has now begun to be powered by our biosimilar portfolio. So let me walk you through where we stand. At present we have 11 biosimilar products on the market or more, which will be covering $16 billion of originated brand sales expected between now and 2027, plus another 9 more after that, covering $58 billion of originated brand sales. So what does that mean? It means our portfolio has grown by more than 50% over the last 3 years, and it's beginning to have a meaningful impact on our generics business. It's worth noting that we're starting to launch biosimars on a regular basis in Europe. So to wrap up and before I hand it over to Eric, I want to restate our 2027 financial targets on the pivot to growth journey. Revenue mid-single digit non-GAAP operating income of 30%, net debt to EBITDA of less than 2% and cash to earnings of 80%; and with that, I will hand over to my colleague, Eric.

Eric Hughes executive
#4

Thanks, Richard. And like Richard said, I enjoy walking through this slide for 2 solid reasons. First, there's a significant difference we can deliver for patients across quite a few indications; and second — it stands for 4 submissions within the coming 5 years. And once the MLX deal is closed, that becomes 5 submissions over the next 5 years, which is a genuine achievement for the teams at Teva and the R&D group, and we're really enthusiastic about that future potential in our pipeline. To start, I'd like to discuss olanzapine LAI. I have something of a late-breaking update; our EU submission was just completed yesterday, and we'll be awaiting validation of that acceptance from the EU over the coming months. So that's very exciting. The team did an excellent job speeding up that submission; and as you're aware, we filed with the FDA back in December, and we think the review process is proceeding as expected, and we look forward to approval by the end of this year. Now turning to the dual action rescue inhaler program, our DARE program in Phase III — I'm very pleased that enrollment is now finished for the large Phase III program known as FLAIR; we enrolled more than 2,700 patients. And what matters even more about this big study is that we have a very large sample size of both pediatrics and adolescents within it, which is a crucial piece of this program because 25% of patients with asthma are pediatrics and adolescents. And our proprietary dry powder inhaler is uniquely suited to be truly beneficial for that patient population. I'm also glad to share that more than 60% of the events have occurred as of now. So we remain on track for completion of events for this study by the end of the year. Moving to our first milestone that we announced in a press release back in February for duvakitug. That was our maintenance data. And just to recap, keep in mind, this study examined ulcerative colitis and Crohn's disease patients with an induction period of 14 weeks, and they rolled over into a maintenance period lasting 44 weeks; now maintenance matters greatly because this is a chronic disease and patients who live with it cycle through therapies often. So having a drug that can sustain its response and continue working for years matters greatly. So we were very pleased to see that the data at our 44-week time point demonstrated strong maintenance. We had Ulcerative Colitis patients maintaining 55% of their — or 56% of the response at 44 weeks for Ulcerative Colitis; and for Crohn's disease, for the endoscopic response, they maintained 55% of that response at the high dose; and it's also good that we saw a dose response between the low and high dose. And you should keep in mind, this is administered subcutaneously every 4 weeks during maintenance. Alright, so patient-friendly with good results — that part's clear. But where does that leave us in terms of comparison? We're genuinely excited about the data we have here, which we believe is best in class. That said, if you step back and survey the whole landscape, this could potentially be best in disease. Our numbers hold up well when you run a cross-study comparison against the TL1A agents currently in development, the approved anti-IL-23s, and the improved JAKs. So that's favorable — we're quite hopeful and eager to find out how the Phase III program reads out. The fundamentals behind duvakitug are really solid. This antibody offers high potency, high selectivity, and immunogenicity — our induction data demonstrated very favorable outcomes across that 14-week induction period, all administered subcutaneously, and the safety profile remains strong and favorable. Then we replicated those findings with robust maintenance data extending out to 44 weeks now, once again with good safety, Q4 dosing, and everything subcutaneous. So the fundamentals are in place, which brings us to the final slide on duvakitug — the Phase III study. We're collaborating very closely with our partner, Sanofi. I'm pleased to share that the study remains on track and has gotten off to a good start, and we're aiming to speed this program up. In my view, the Sunscape and Star scape programs will be enormously important for defining this class of molecule. Now turning to another antibody born and raised at Teva, originating from our Sydney labs — that's our anti IL-15 program. It's presently in 2 proof-of-concept studies, one for vitiligo and one for celiac disease. What's exciting about this molecule, much like Duvakitug, is that it could someday gain approval across multiple different indications. So today we're examining its lag on Celiac, while alopecia areata, atopic dermatitis, and eosinophilic esophagitis all represent possible future targets for this molecule. Just to review what we expect this year: we have a proof-of-concept study underway in Vitiligo. One key takeaway from this study — and I want to emphasize this, because I think it points to a potentially great product profile — is that we're conducting a 24-week study, yet only 2 shots are given subcutaneously, once a day at 0 and once at week 12. Then we'll have a week 24 readout for the VAS score, which serves as the registration endpoint for Vitiligo; those results should arrive at the close of this first half. After that, in the second half, our celiac disease program will read out. Again, to show the product profile, this is a single-dose study with a readout following 12 weeks of therapy; and this is a classic proof-of-concept study in which we administer a dose of either active or placebo, then challenge the patients with 6 weeks of gluten, roughly 3 grams per day. So — and then at 8 weeks, we'll obtain the biopsy. And what we're going to examine and share during the back half is how well the gut is shielded from harm, measured through the Willis decrypt depth ratio taken from an endoscopic biopsy; so that's a really thrilling program. I believe, as we move toward the data, that this marks the initial occasion for vitiligo in the latter six months for CWI. And lastly, the final program I want to bring up, since I believe it's such a significant indication for multiple system atrophy, is our Emerson program. This is a differentiated small molecule capable of penetrating the brain that goes after alpha-synuclein right at the origin of the pathogenic aggregations. We remain on schedule. Enrollment is progressing quite well. As a matter of fact, we intend to over-enroll this study to guarantee it's robust, while still keeping it on time, and we remain on track for the futility analysis at the close of this year. Once again, we hold orphan designation along with Fast Track designation from FDA. So I'd like to wrap up with our really thrilling slide regarding the milestones we're hitting this year. First, I noted the duvakitug readout in maintenance — we felt there was excellent data demonstrating the worth of duvakitug. The anti-IL-15 program touched on a bit of oligo in the first-half readout, and then CAC disease in the second half. The DARA program has fully enrolled its Phase III program, on track for the final readout and final exacerbation by December. Emera Soman, we're on track toward the futility analysis. The Ondapina-LAI program is currently under FDA review, and we completed our submission just yesterday in the EU. And finally, we'll have IL-PD-1-IL-2 data at the close of this year. So it's a fantastic year. I'm grateful for all the work being done in R&D and the additional effort everyone is putting in. And with that, I'll hand things over to Eli Kalif.

Eliyahu Kalif executive
#5

Thank you, Eric, and hello everyone, good morning and good afternoon. I'd like to begin my review of the Q1 '26 results with these key messages: To start, we kicked off the year with a strong first quarter, fueled by the ongoing momentum of our innovative portfolio. Next, the rising share of innovative revenue, combined with our transformation programs, gives us confidence to enhance margins across 2026 and stay on track toward our 30% operating margin goal in '27. Third, we're keeping a close eye on the geopolitical situation in the Middle East. Our operations have continued without interruption, and there's been no material effect on our 2026 guidance. Finally, our capital allocation strategy stays centered on advancing our pivot to growth strategy and generating shareholder value. The deal to acquire Molex and the possible share buyback program demonstrate our continued dedication to a disciplined approach to capital allocation. Now let's turn to Slide 35. Before diving into the results, I want to remind everyone that our Q1 '25 financial results contained roughly $75 million in revenue contribution from the Japan business venture, which was divested on March 31, 2025. For a like-to-like comparison, I'll remove this business's contribution from last year when we discuss our financial results for this quarter. Now let's begin with our Q1 GAAP performance. Our Q1 revenue came to roughly $4 billion, up 4% in U.S. dollars, or down 1% in local currency versus Q1 '25. Our key innovative products, AUSTEDO, AJOVY and UZEDy, kept up strong momentum, largely offsetting reduced generics stemming from the lost revenue from generic reveled that we had anticipated. GAAP net income and EPS came in at $360 million and $0.31, respectively. Now turning to our non-GAAP performance. Our non-GAAP gross margin in Q1 '26 was 52.9%, and this gross margin result beat our expectations, primarily driven by continued robust growth in our key innovative products and a favorable product mix within generics. Non-GAAP operating margin fell roughly 50 basis points year-over-year to 24%, mainly because of higher planned investment in sales and marketing to support our innovative growth. All in all, we closed the quarter with non-GAAP EPS of $0.53, compared to $0.52 in Q1 '25. Our free cash flow in Q1 was $188 million, up from $107 million last year. As I mentioned on our prior earnings call, our Q1 '25 results included approximately $300 million in revenue contribution from our generics Revelmid. Excluding this contribution, along with the divested business in Japan, our revenue rose 7% in local currency and adjusted EBITDA by 28% in Q1 '26. On Slide 36, I'd like to remind everyone of the margin trajectory I presented last year in May and how we intend to move from roughly 26% operating margin in '25 to our 30% target in '27. That works out to about a 400 basis point gain across 2 years. It comes from the ongoing rotation of our portfolio into innovative products with high growth and high margins, plus $700 million in cost reductions we anticipate from our transformation program, and this is true even with the revenue we will lose from our Generics reveled in 2026. During 2025, we moved considerably closer to those objectives, lifting our underlying operating margin to 26.8%, a figure that came in above what we had initially expected for 2025. Now on Slide 37, our margin expansion journey carries on in '26, and the first quarter gave us a solid beginning. Broadly speaking, we are reshaping Teva into a business with structurally higher gross margin, supported by a growing mix of innovative products and by transforming our manufacturing cost base; on top of that, our OpEx transformation lets us hold operating expenses steady as a percentage of revenue, since we plough substantial savings from our G&A back into our innovative portfolio and pipeline, putting us in position for growth in both the short term and the long term. Let's go to Slide 38. We are likewise achieving considerable progress across our Teva transformation programs so that margin improvement can be sustained. Through Q1, we kept carrying out our targeted programs and stayed on track to reach roughly 2/3 of our total $700 million savings target by the close of 2026. Tied to these programs, we have already booked approximately $205 million in restructuring costs in 2025 along with a cash outflow of approximately $100 million. In Q1 '26, we booked another restructuring cost of approximately $25 million; and across the full year of 2026, we expect a cash outflow of approximately $90 million to $100 million, every bit of which is already interrupted in our guidance. These transformation efforts, together with our continuing portfolio shift towards innovative products, give us confidence to grow underlying EBITDA in '26 and in '27 and to hit our 30% operating margin target by 2027; now on Slide 39, allow me to offer a few extra details about our agreement to acquire Emalex, with a couple of key messages. First, as Richard mentioned earlier, Emalex fits extremely well with our pivot to growth strategy. Second, we are keeping a strong balance sheet, with no change to our 2027 leverage target of 2x net debt to EBITDA. Now to the key terms of the transaction. The upfront consideration is $700 million in cash, plus additional commercial milestones of up to $200 million; we anticipate the transaction closing in late Q2 or early Q3, subject to customary closing conditions. On to the financial impact. We expect the product to carry a gross margin profile of approximately 80%, subject to regulatory approval and launch in 2027. I will go over changes to our 2026 financial guidance reflecting these acquisitions on the next slide; but importantly, we expect MLX to contribute meaningfully to our revenue growth and margin expansion once ecopipam is launched and scaled, and to be accretive to our non-GAAP EPS starting in 2028. And lastly, our 2027 financial targets are still on track, and that includes a 30% operating margin. We anticipate that the increased operating expenses tied to Emalex in 2027 will be offset by the first revenue gains from Eoin once it launches, along with further efficiency initiatives. Let me now move to our 2026 outlook, which is on Slide 40. As I said before, we got off to a solid start this year, with strong underlying revenue, margins, and cash flow in Q1. That was largely balanced out by a difficult comparison to last year's generics reveled revenue. We're also enthusiastic about the Emalex acquisition, which should further sense and build on our robust commercial infrastructure in the CNS area. Given our Q1 results and what we can see for the remainder of the year, we are reaffirming our 2026 outlook range on an underlying basis, excluding Emalex for all financial metrics we provided on our Q4 earnings calls, including growing our EBITDA in 2026. But even though Teva is buying 100% of Emalex shares, we believe the acquisition will be accounted for as an asset deal. As a result, the upfront consideration of $700 million will go through the R&D line as IP R&D expenses in the P&L. We also expect roughly $75 million of extra operating expenses in 2026 tied to Emalex beginning in Q3, which includes the transaction costs.

Eliyahu Kalif executive
#6

The adjustments to our 2026 outlook for operating profit, EBITDA and EPS are progressively capturing this extra $775 million in expenses tied to the acquisition. Our free cash flow guidance range stays at $2 billion to $2.4 billion, with no revision. If you set aside the Emalex acquisition, the outlook range for our effective tax rate, 16% to 19%, is likewise still the same. Turning to the next item, we still anticipate that 2026 non-GAAP gross margin will land between 54.5% and 55.5% and during the year. We expect operating expenses to come in at 27% to 28% of revenue, and the first half should run above the second half, which mirrors planned investment made in the first half, together with a larger benefit in the second half from cost savings under the transformation program; given those expected operating expenses plus the transaction costs tied to Emalex, we now look for our 2026 operating expenses to sit near the upper portion of that 27% to 28% range. Finally, let me give you some guidance on how quarterly progression should be viewed for the remainder of 2026; we still anticipate that revenue will rise gradually as the year goes on. In addition, Q1 revenue came in a bit above what we had expected, thanks to channel destocking that was less than anticipated and because the timing of certain orders shifted from Q2 into Q1. Because inventory levels in the channels are still high, these dynamics could shift as the rest of the year unfolds. Moreover, as we noted last quarter, we anticipated steady revenue in Q4 '26 that would decline versus the prior year, driven by the different purchasing partners and the pricing environment we expect before IRA implementation arrives in January '27. Our non-GAAP margins should also climb gradually as the year progresses, tracking both the revenue path and the savings generated by the transformation programs now underway. That said, we look for margin in Q4 to hold steady compared with Q3, which mirrors the channel dynamics we anticipate around a state in Q4, 2026. Finally, our approach to capital allocation stays centered on advancing our Pivot to Growth Strategy. Across the past few years, we have achieved meaningful progress in fortifying our balance sheet, and we now sit a short distance from our target leverage of 2x net debt to EBITDA as well as an investor-grade credit profile. We feel we are well positioned to reach these objectives, and the major credit rating agencies have acknowledged our execution. The progress achieved so far lets us keep investing organically in our innovative portfolio and pipeline while also giving us flexibility to carry out thoughtful, accretive business development that builds long-term shareholder value, exactly as we are doing with Emalex. Beyond that, our Board of Directors has directed management to plan a share repurchase program that could be put in place subject to satisfying applicable legal requirements. When we move forward with buybacks, both the schedule and the precise dollar figure will need additional sign-off from the board. A range of things will play into that decision, such as how the market is behaving, where our stock is trading, and what other chances to invest come up that fit with our pivotal growth strategy, along with the virus and other factors. Our view is that putting capital to work this way could boost long-term shareholder value even more, and at the same time we'd keep the financial flexibility needed to keep funding our business and carry out our pivotal growth strategy. So with that, I'll turn things over to Richard now for his closing remarks.

Richard Francis executive
#7

Thanks, Ali. Now let's turn to this slide. I'd like to restate the reasons we're enthusiastic about the Emalex transaction and why it lines up so well with our Pivotal Growth strategy and the business development criteria we've established. Let me walk through each of them. To begin with, this is an uncommon neurological asset that sits right in the middle of our core therapeutic area. Next, it fits naturally within our CNS franchise, drawing on the commercial infrastructure and capabilities that are already established. Third, it's accretive financially, producing revenue growth beginning in 2027, margin expansion starting in 2028, and generating strategic as well as financial optionality down the road. Fourth, the risk profile looks very appealing. Pivotal studies have finished. The program is thoroughly understood, and we anticipate a regulatory filing in the second half of 2026. And last, this deal doesn't affect our pledge to reach 2x net debt to EBITDA by 2027. In short, this is precisely the kind of disciplined, value-creating transaction we told you we would go after. I'm thrilled about what this will mean for patients who currently have very few treatment choices. Before wrapping up, allow me to remind you of several drivers that we think make Teva an appealing investment, and of how our Pivot to Growth Strategy keeps delivering as planned, turning Teva into a top-tier innovative biopharma company. We anticipate that our innovative portfolio will keep fueling growth well past 2027. Right now it's anchored by AUSTEDO, and we are restating our goal of hitting more than $2.5 billion in 2017 and over $3 billion in peak sales, together with our innovative products. As you noted, with AJOVY, we'll keep pushing our product mix and profitability forward. And as I mentioned, we're also getting ready for the exciting innovative launches ahead, beginning with olanzapine this year. Then, for my last slide, the growth journey carries on. Innovative brands delivering double-digit growth for upcoming launches, Amla's appealing acquisition of a first-in-class neuroscience treatment that aligns with our strategy and financial targets, near-term value-unlocking milestones from our world-class pipeline, and a stable outlook for our generics powerhouse, all accelerating the Pivot to Growth Strategy. With that, I'd like to open the floor for questions. Thank you.

Eliyahu Kalif executive
#8

Thank you, Richard. <<operator_script>>.

Louise Chen analyst
#9

Congrats on the quarter. I'd like to ask about the Emalex acquisition, and whether you could share more detail on the synergies with your CNS franchise, particularly on the pediatric side. Then, as a follow-up, how are you thinking about this asset's peak sales potential? And what sort of assumptions back that up?

Richard Francis executive
#10

Luis, thanks for the question. Yes, so regarding IcoPipan, this asset has us quite enthusiastic, given the substantial unmet medical need. There are roughly 100,000 pediatric children living with Tourette's, and only around 50,000 of them actually enter therapy. And as I mentioned, fewer than 30% remain on therapy beyond 1 year. So obviously, a considerable unmet medical need exists. As I discuss this, you're probably quite familiar with the work we've done with AUSTEDO and, to some extent, you set. So returning to the portion of your question about what the synergies are: we clearly have synergies across many parts of our business, from patient services to managed markets to MSLs and, to some extent, our sales force. We will need to establish a small pediatric sales force focused on nicotine. That said, it's worth noting the deep expertise we possess in movement disorders here at ever; we have it with neurologists, and we have it with the psychiatric community. So I believe for that reason, we're very excited that we can truly offer some meaningful hope for what is a very different condition in children. As for your question about big sales, I'll simply return to this being a significant opportunity. And as we get closer to launch for this product, we'll begin to give an idea of what we think this could be; but I think right now, we're just thinking about the unmet medical need, the lack of treatment options, and a significant unmet medical need from a patient perspective. Thank you for your question, Louis.

Glen Santangelo analyst
#11

Let me start, Richard — obviously the innovative portfolio is showing very strong growth, and I believe during your closing comments you brought up again that figure of more than $2.5 billion in sales for a stead in '27. So I'm simply attempting to square that with certain things you said earlier in the year regarding where you anticipated growth in the low single digits. Once we break down this quarter and adjust for FX, the Japan business venture, and generic Revlimid, it appears to us like a quarter with 7% growth. So I was curious, Eli, whether you might be able to verify that. After that, I'm attempting to square the current growth rate of the business against what you expect, which is low single-digit growth in '27. Naturally, you don't want to guide on '27 right now, but as we look ahead, you see alone arriving at this point, and now you have Ecopia, which might be a modest contributor next year? I'm just attempting to square all those significant moving pieces regarding how we ought to think about the remainder of this year and the growth rate going into next year?

Richard Francis executive
#12

Glenn, I appreciate your question. Let me attempt to break it down. What I think I'm hearing is perhaps — and perhaps you can tell me — that perhaps your sense is we might be a touch conservative as we head toward 2027. Is that what you're asking?

Glen Santangelo analyst
#13

Yeah, yeah. It sort of seems, Richard, that right now you're expanding at a much quicker pace than that, and you anticipate perhaps a slight increase for AUSTEDO in the coming year, along with a bit of input from what's in development. I'm merely attempting to square your thinking regarding that expectation of low single digits for the upcoming year.

Richard Francis executive
#14

All right. That makes sense now. Okay, so I appreciate you clearing that up; so I believe regarding—let's begin with AUSTEDO in particular. I believe, as I mentioned and as Eli mentioned, several factors are in play here. And one of them, and likely the most significant factor, is the way the IRA has an effect as a sort of pre IRA, meaning Q4. What occurs with our inventory, what occurs with the channel? Will there be a reduction owing to the pricing shift in 2027? That's difficult to grasp and forecast. So I believe for one of those reasons — for that reason, I believe we must be cautious with AUSTEDO and observe how this unfolds. Do we hold any caution, concern, or worry regarding the untreated patient group that still must begin AUSTEDO? Do we hold any concern regarding our capacity to carry out and bring more patients onto AUSTEDO, onto the correct dosage, onto the correct adherence and persistence programs? No, not at all. We stay extremely, extremely confident regarding the long-term expansion of AUSTEDO, and that's why I restated the $3 billion peak sales; it's merely a matter of timing there, Glenn, and merely observing how that unfolds. Regarding a few of the other growth drivers you mentioned and Jovan soon to be olanzapine — as you're aware, we typically prefer to really have a couple of quarters behind us to truly comprehend how this appears; so we don't sort of get ahead of ourselves. So that's what we're considering. So I believe perhaps when we discuss 2027 guidance, we'll reach the end of the year and be able to provide clarity on that; but I believe one quarter is — we're happy with the quarter, but let's have some additional quarters behind us before we begin forecasting what the future might be; so hopefully, that assists you. But I'm happy that you notice the strength in the underlying innovative business. And let's discuss what that might be in '27 and beyond; but perhaps to wrap up for me, I'd say it's a bit beyond '27, '28, '29. I hope you can perceive the chance for us to keep expanding the company, keep expanding our innovative portfolio, and keep expanding our gross margin and therefore keep expanding our EPS. Thanks for the question, Glenn.

Matt Dellatorre analyst
#15

Nice work on the robust quarter and the announcement of the deal. Perhaps starting with how we're thinking about capital allocation in general. Considering free cash flow between $2.5 billion and $3 billion across the coming several years, might you offer a view on what constitutes a reasonable base case right now regarding how you'd spread that across possible additional BD, perhaps share repurchases, and then more debt pay down. And then perhaps 1 on the branded pipeline. What's the current outlook for the indication expansion strategy regarding duvakitug? And is there anything in particular you're watching when it comes to the competitive landscape this year or in the months ahead?

Richard Francis executive
#16

Matt, thanks for that question. And obviously, since I'm speaking for some short throw, I'll pause briefly and get in hand, the capital allocation to Eli and then the 2 new indications to Eric? Eric, over to you.

Eric Hughes executive
#17

Alright. Thank you for that question, Matt. So, look — we closed out the quarter with $3.7 billion in cash sitting on the balance sheet. When you consider the midpoint for this year, roughly 2.2 in free cash flow, we've already produced close to EUR 200 million, and there's about another EUR 2 billion still to come, which brings you to around EUR 5.7 billion. Once you factor in the MLX closing, that figure moves to EUR 5 billion, and we've got an additional tranche due in October of roughly EUR 1.8 billion to pay. So by the time the year wraps up, chances are we'll be sitting above EUR 3.2 billion — from where we stand, that's a very solid balance sheet. As we continue forward, growing our EBITDA and completely reshaping our gross margin expectations toward a $2.4 billion to $3 billion type of run rate past, I'd say, 26 million on free cash flow. Regarding what we announced this morning on the buyback, it's essentially a piece of the natural progression in how we allocate capital, one that now really centers us on driving shareholder value to the maximum. In effect, it hands management extra optionality for deploying capital. And the reason we can do this is that our balance sheet has grown stronger. Looking ahead, what we expect to see is perhaps another 1 or 2 deals in the couple-hundred-million range; nothing larger than that is on our radar near term. Should some opportunity present itself, we'd need to arrange other financing. Our revolver, at EUR 1.8 billion, remains untouched — we're not drawing on it — and as I said, EBITDA is climbing along with our free cash flow. On that basis, I'd say any such quantum shouldn't push us away from our 2x net debt to EBITDA; the thinking behind this is to reach 2x net debt to EBITDA and then, moving ahead, manage our debt so we're certain we retain sufficient flexibility to expand the business.

Richard Francis executive
#18

Thank you, Eli. And now, Eric, on the 2 new indications for duvakitug.

Eric Hughes executive
#19

Absolutely, and thanks for bringing that up, Matt. As we've consistently noted, Dubai holds tremendous promise across a wide range of indications. Together with Sanofi, we categorize these opportunities into T2, non-T2, and fibrotic indications. We also have a well-defined process for selecting among them, guided by market size, scientific rationale, regulatory likelihood of success, and how quickly we can move. So we're keeping those indications under wraps for now, and we'll share them before this year wraps up. I believe there's a lot of enthusiasm surrounding that. That said, one thing I'm particularly pleased to observe at this moment is the dedication and pace with which we're examining the Phase III programs in inflammatory bowel disease — the potential in that area is enormous. I also think we stand apart significantly from the other molecules currently available, and that's the major achievement we've been concentrating on up to now. But we will be disclosing those. In my view, the indications within this space are going to progress rapidly. Thank you.

Dennis Ding analyst
#20

Regarding the Emalex deal, I've got 2 questions. Your slides never actually bring up the adult population, yet the Phase II data showed a hit for both pets and adults as a secondary endpoint. So I'd like to know whether you're expecting a broad label covering peds and adults alike. And beyond the 50,000 children on therapy that you mentioned, how meaningful could that be for the TAM? Also, if you could comment on the efficacy seen in the adult-only population, that would help. Then, as a follow-up, could you help us pin down pricing? You said rare in your slides, but that's still quite broad.

Richard Francis executive
#21

Thanks, Dennis. What was that last part, pricing? Alright; Eric, I'll tag team the first 1 with you. Just so it's clear, this is a pediatric treatment cabin for pediatric Tourette — let me be clear on that. And looking at the patient population, most of them are pediatric. So I hope that answers your question. On pricing and rail and orphan, yes, we believe that given the significant unmet medical need, and thinking about the size of the population, that lets us have a pricing within the range that is normal for orphan and rare. I hope that answers your question. Dennis, do you want to add something to it, Eric?

Eric Hughes executive
#22

Yeah, and yeah. Thank you, Dennis. Regarding your question on adults — the Phase III trial included only a modest number of adult patients. Those efficacy findings moved in the same direction as what we saw in pediatric patients. But I'd add to Richard's point: the efficacy in pediatrics matters a great deal here, since with a novel mechanism such as this one — a D1 receptor antagonist — and its safety profile, especially in pediatric patients — you don't see weight changes. You don't see metabolic findings. You don't see the extra paramenal signals that a D2 receptor antagonist would produce. This product can deliver a strong efficacy profile, but even more importantly, the safety for the pediatric population is something we take real pride in being part of, and I believe that's where the true value lies.

Jason Gerberry analyst
#23

I have a question about the generics pipeline. Teva has a settlement allowing it to release a generic version of the Tyvaso nebulizer during this year, yet it decided against doing so for business reasons. I'm curious whether the company might rethink that, since the drug and its dosage format are expected to enter the IPF category, which I believe some analysts value as a $4 billion to $5 billion indication. Also, I think a license would provide you with sole-source generic status for a pre extended period of time. So I'm just wondering what's happening there. Is it just hard to secure a generic approval? Then for my follow-up, I saw on your slides regarding the IL-15 for Vitiligo — it's now shown as an accelerated path with 2031 time to BLA, whereas previously it was a range of 31% to 34%. So have you had a regulatory interaction, and are you now confirmed on that accelerated path?

Richard Francis executive
#24

Jason, thanks for the question. As for the generic pipeline, we don't discuss our generic pipeline for competitive reasons as well as legal and others. So I'm sorry, I can't really give you any more color to that. But I'll let Eric give you some color on the.

Eric Hughes executive
#25

Absolutely. Jason, I appreciate you picking up on that. For this announcement, we made that adjustment. The real reason behind it is that the team is delivering on execution. There's a very clear path forward for how we'll design our Phase II and Phase III study, so we have more confidence in our execution right now. But thanks for catching that.

Umer Raffat analyst
#26

I figured I'd take a moment to dig into the Emalex deal too. To start, in a typical pharma outfit you end up taking on a bunch of molecules that each carry their own expiration dates. What seems like an edge for you all is that you're the ones choosing how to layer on the LOEs. So my first question: given that this molecule is an old Merck drug, there's likely no composition patent, and the method of use probably ties to the early 2030s thanks to some of the earliest Tourette work dating back to 2014 — is the real protection here just orphan exclusivity? And would that basically overlap with the Osteo IPs? That's #1. And #2, has the FDA given any preliminary feedback on whether the trial duration so far is enough to satisfy them regarding suicide ideation and neurosigdisorders broadly?

Richard Francis executive
#27

Appreciate the questions. Our expectation is that icupipam gets covered by orphan drug exclusivity. That provides 7 years starting from the FDA approval date, which lands us somewhere in the 2033, 2034 time lines. On top of that, Emalex was granted a patient expiring in 2035 covering methods of treating Tourette syndrome using icatibant. That pattern will likely qualify for patent term extension. — and Alex has filed another application covering methods of treating interest in them, which could expire in 2043, if granted. So — and circling back to your comment, Oman AUSTEDO XR, we also believe without going into the detail that we have a clear path of patent extension into the 2040s as well for the XR formulation; so I think that, I think we feel pretty good. But when it goes on to the question. I'll hand that to Eric.

Eric Hughes executive
#28

Absolutely, and thanks for raising that, Umer. There's a lengthy record of development behind this molecule, along with a substantial collection of data. The work actually began at Plow, a firm where I was previously employed, and afterward continued at Merck — though our main focus here is the Tourette's effort, which encompasses two well-controlled trials. As you'll recall, one was a Phase II trial demonstrating responses while on treatment as well as shifts from baseline on the Yale score, and the other was a randomized withdrawal Phase III trial that demonstrated strong durability relative to placebo — both reaching statistical significance and showing solid power. The dataset coming out of that orphan disease setting is strong. It doesn't satisfy every requirement, yet given that this is an orphan disease, we have reasonable confidence that combined with the compound's prior history, it will be adequate for approval. Now, regarding — I mean, to get at what you specifically asked about suicidality: rates of suicidality were very low, only a few cases, and in fact those were evenly distributed across the placebo-controlled portions of the trials. Beyond that — and this matters more — the trials were conducted with great rigor, employing numerous assessments across a wide range of domains, especially suicidality and extrapyramidal syndrome. With such intensive monitoring, no signal whatsoever emerged concerning suicidality or any baseline shifts. Even more significantly, on the extrapyramidal syndrome front, no motor-event disorder or signal appeared. The reason I mention all of this is that these were very meticulous placebo-controlled studies showing no weight gain, no metabolic alterations, and none of those extrapyramidal motor-dysfunction symptoms you tend to observe. That sets it far apart from the D2 receptor antagonist — something I, as a parent, would ordinarily be reluctant to give a pediatric patient, since antipsychotics of that kind can produce changes that are sometimes permanent. So the profile of the DD1 agonist strikes me as very well suited to this patient population, with side effects that are very well tolerated. And even more crucially, if you've got an efficacious medication the patient is actually able to remain on, that's what counts. Efficacy means nothing if the patient can't keep taking it. In fact, in their long-term 1-year study, within the open-label extension at the 1 year mark, 66% of patients remained on the drug, versus 20% or 23% with a typical antipsychotic treatment. So taking all of this together, I believe the picture is favorable, and I believe regulators would look on it positively.

David Amsellem analyst
#29

I’ve got a few; first, regarding Emalex, building on what was just asked, do you expect a REMS will be required for suicidal ideation or possibly other risks? I’d just like some insight into how you’re thinking about that; then, when you consider other indications, I believe Emalex had a program in restless leg syndrome. My understanding is it was augmentation. So could you discuss your plans there? And finally, for Richard, I think you’ve referenced your M&A strategy as it relates to expanding the neuroscience pipeline, pursuing that more inorganically through M&A, while for immunology you’ll concentrate more on organic development. Does that remain true? Or are you adopting a more flexible stance when you consider those 2 verticals?

Richard Francis executive
#30

David. I appreciate the question. I’ll pass the first 2 to Eric.

Eric Hughes executive
#31

Right, thanks for asking. As far as we can tell, no REMS will be attached to this program. With drugs in this particular class, a black box warning for suicidality is something you would probably anticipate, though that is standard for medications of this kind. Regarding the restaurant legs syndrome indications, we have not yet reached a final call, but that is a possibility we could consider down the road.

Richard Francis executive
#32

Now, regarding M&A, David, you're correct that we usually discuss neuroscience as something pursued through acquisitions, while immunology tends to come up as something we develop from within, in terms of our pipeline. That being said, everything ultimately ties back to what Teva is aiming for — building a biopharma company of world-class caliber and ensuring we deliver value to patients and shareholders — and it all circles back to capital allocation and figuring out the best possible approach for deploying that capital. So even though those patterns hold true, we continue to examine, search, and consider ways to genuinely strengthen this Pivot to Growth Strategy on an ongoing basis. We remain highly disciplined about what we take on and the manner in which we do it, whether that's internal or external. When you have an internal pipeline, capital allocation is unavoidable; and we approach that with the same discipline as we would for anything external. But on the whole, your recollection is accurate, and that aligns with our strategy. Thank you.

Chris Schott analyst
#33

I had a couple of items. Starting with Emalex — I realize you won't address peak sales. Still, could you say anything about how the launch trajectory should be modeled following approval, in light of the unmet need? I'm simply attempting to grasp whether payer-related factors might slow the uptake, or whether things could move fairly fast given the market as it stands right now. Then my second item returns to AUSTEDO and those quarterly step patterns. I completely grasp the point regarding 4Q. Could you, however, describe the upcoming several quarters? It appears some destocking had been anticipated during this period and might not have happened entirely. Is there anything to bear in mind regarding 2Q and 3Q that might produce growth rates under the fundamental volumes, and so forth? Any insight would be welcome.

Richard Francis executive
#34

Chris, yes, I appreciate those questions. Regarding Emalex, I won't provide peak sales guidance, though I will offer ramp-up guidance. Look, I believe we return to what you flagged in your question — a substantial unmet need within a patient population that is pediatric, which clearly receives considerable focus and attention; nonetheless, as is typical at Teva, we prefer to remain quite thoughtful and diligent, truly grasping what this might look like. The unmet need is large. We're enthusiastic about it. I don't wish to be overly evasive, yet when it comes to the matters you raised — patients beginning therapy, solid access, suitable access — those are what we prefer to reason through. So I think your enthusiasm, which I detect in the question, is fitting, though we'll require somewhat more time before we can begin offering you a genuine line of sight there. On AUSTEDO, yes, we simply didn't observe the drawdown during Q1 that we had anticipated — so how does that unfold? Likely it unfolds somewhat into Q2 and Q3. Yet after that comes the basic issue concerning Q4. So we'll just have to watch how it develops. What I always return to, what I discuss in these internal conversations, is: fine, but what are we accomplishing on the leading indicators — the TRx, the milligrams, everything we're doing regarding our coverage, new prescribers, the depth of prescribing? And every one of those indicators appears very much on track; so I feel quite good about that, since my line of sight is the $3 billion plus. It isn't really the near term — I feel we have that line of sight clearly laid out. That's how I consider how it unfolds into Q2 and Q3; just keep those in mind — the underlying indicators are good. About destocking — we'll watch how it unfolds during Q2, and afterward, once we have that data ourselves in Q2, we'll likely share a few more indications with you, saying this is how we believe it might trend across the remainder of the year. So I hope that answers it, Chris. Thanks for asking.

Ashwani Verma analyst
#35

Regarding that $700 million disbursement for BV that you're carrying out, in what way does it shift your schedule for reaching investment grade debt — can that still be reached during this year? Then, as a second question, given what's happening geopolitically in the Middle East, does that have any effect at all on your freight or shipping expenses, or cause any difficulties when it comes to moving materials into and out of various regions?

Richard Francis executive
#36

I'll let Eli take both of those.

Eliyahu Kalif executive
#37

Ash, I appreciate the question. So to start with, when it comes to the path toward reaching investor grade this year, nothing is going to shift. As for that $700 million, it's really an amount that will come through as anticipated, given how the deal is structured, into the IP R&D line, and also from our balance sheet on a cash basis. But based on how we're tracking on EBITDA growth this year, and continuing to produce cash, we don't expect this 1 to have any effect on the metrics we need to hit in order to become investor grade. Now, on the other point — look, we're watching the situation involving the coffin with Iran in the Middle East very carefully. And I can tell you there were, let's call it, a handful of items — a nominal bump in certain spending tied to transform portation and some energies — but this 1 is really quite small, and we're able to keep an eye on it, and everything, given that our cost base for '26 already sits within the range in our guidance.

Richard Francis executive
#38

Thanks, Eli. Thanks, Ash. Next question, I think a final question I believe.

Leszek Sulewski analyst
#39

I’ve just got 1 question. How confident are you about the Viggo readout that’s coming up, and afterward Antheia, considering those readouts? Then, tied to that, how competitive do you expect the data will need to be compared with what’s been observed from the IL-2, IL-15 dual inhibition strategy?

Richard Francis executive
#40

Thank you. I appreciate the question. I’ll pass that directly over to Eric.

Eric Hughes executive
#41

Absolutely, and thanks for bringing that up. At this stage, I'd say the target for the IL-15 program keeps gaining more validation. What we should measure ourselves against, I believe, is the latest Phase II and Phase III outcomes for the oral JAKs — those are systemic therapies today. The newest data available, in my view, sets a solid benchmark. Keep in mind that our results are based on 24 weeks, and you should always line up the timeframes, since the endpoints — the disease evolves while on treatment as time passes — so what we'll present is 24-week data, which is why I'd pick that from the Phase II and Phase III findings. I also believe our program could be competitive and could offer a systemic option that patients can conveniently receive as a subcutaneous injection once every quarter. That makes for a profile that stands apart from whatever is currently in development.

Richard Francis executive
#42

Appreciate that, Eric. That wraps things up for this call, I believe. Thanks for every question you sent our way and for the attention you've shown Teva; we're eager to bring you another update when Q2 arrives. Many thanks to all of you. Take care.

Operator operator
#43

This concludes today's conference call. Thank you all for joining.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teva Pharmaceutical Industries Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Teva Pharmaceutical Industries Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.